Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists

Amino Acids

Volumn 43, Issue 2, 2012, Pages 617-627

  Kwiatkowska, Anna ^a   Ptach, Monika ^a   Borovicková, Lenka ^b   Sina Slaninová, Jir ^b   Lammek, Bernard ^a   Prahl, Adam ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Antidiuretic hormone; Arginine vasopressin (AVP); Atosiban; Binding affinity; Neurohypophyseal hormones analogues; Oxytocin antagonists

Indexed keywords

1 AMINO 4 PHENYLCYCLOHEXANE 1 CARBOXYLIC ACID; ACYL GROUP; ARGIPRESSIN; ARGIPRESSIN DERIVATIVE; ATOSIBAN; CARBOXYLIC ACID DERIVATIVE; FUNCTIONAL GROUP; OXYTOCIN ANTAGONIST; OXYTOCIN DERIVATIVE; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG;

ACYLATION; AMINO TERMINAL SEQUENCE; ANTIDIURESIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; PRESSOR ACTIVITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; UTEROTONIC ACTIVITY;

AMINO ACID SEQUENCE; ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; CARBOXYLIC ACIDS; CYCLOHEXANES; DRUG DESIGN; FEMALE; HEK293 CELLS; HUMANS; MALE; OXYTOCIN; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, WISTAR; RECEPTORS, OXYTOCIN; VASOCONSTRICTOR AGENTS;

EID: 84864774169     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1109-6     Document Type: Article

References (63)

1. Acher R (1993) Neurohypophysial peptide systems: processing machinery, hydroosmotic regulation, adaptation and evolution. Regul Pept 45:1-13
2. Barberis C, Mouillac B, Durroux T (1998) Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 156: 223-229
3. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, Tribollet E, Manning M (1999) Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect 12:279-292
4. Bielsky IF, Young LJ (2004) Oxytocin, vasopressin, and social recognition in mammals. Peptides 25:1565-1574
5. Bodanszky M, Bodanszky A (1984) The Practice of Peptide Synthesis, vol 83. Springer, Berlin
6. Burn HJ, Finney DJ, Goodwin LG (1950) Biological Standardization, 2nd edn. Oxford University Press, London, p 187
7. Caldwell HK, Lee HJ, Macbeth AH, Young WS III (2008) Vasopressin: behavioral roles of an original neuropeptide. Prog Neurobiol 84:1-24
8. Christensen TC (1979) A chloroanil color test for monitoring coupling completeness in solid-phase peptide synthesis. In: Gross E, Meienhofer J (eds) Peptidess structure and biological function. Pierce Chemical Company, Rockford, p 385
9. Dekanski J (1952) The quantitative assay of vasopressin. Br J Pharmacol 7:567-572
10. Derdowska I, Prahl A, Kowalczyk W, Janecki M, Melhem S, Trzeciak HI, Lammek B (2005) Influence of enantiomers of 1-napthylalanine in position 2 of AVP and dAVP on their pharmacological properties. Eur J Med Chem 40:63-68
11. Fahrenholz F, Boer R, Crause P, Fritzsch G, Grzonka Z (1984) Interactions of vasopressin agonists and antagonists with membrane receptors. Eur J Pharmacol 100:47-58
12. Fields G, Noble R (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214
13. Flouret G, Terada S, Kato T, Gualtieri R, Lipkowski A (1979) Synthesis of oxytocin using iodine for oxidative cyclization and silica gel adsorption chromatography for purification. Int J Pept Protein Res 13:137-141
14. Frank E, Landgraf R (2008) The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol 583:226-242
15. Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629-683
16. Gimpl G, Burger K, Fahrenholz F (1997) Cholesterol as modulator of receptor function. Biochemistry 36:10959-10974
17. Goldsmith SR (2006) The role of vasopressin in congestive heart failure. Cleve Clin J Med 73:19-23
18. Goodson JL, Bass AH (2001) Social behavior functions and related anatomical characteristics of vasotocin/vasopressin systems in vertebrates. Brain Res Brain Res Rev 35:246-265
19. Hernando F, Schoots O, Lolait SJ, Burbach JP (2001) Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142:1659-1668
20. Holton P (1948) A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br J Pharmacol Chemother 3:328-334
21. Insel TR, Fernald RD (2004) How the brain processes social information: searching for the social brain. Annu Rev Neurosci 27:697-722
22. Jard S, Barberis C, Audigier S, Tribollet E (1987) Neurohypophyseal hormone receptor systems in brain periphery. Prog Brain Res 72:173-187
23. Jastrzebska B, Derdowska I, Kowalczyk W, Machova A, Slaninowa J, Lammek B (2003) Influence of 1-aminocycloheksane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties. J Pept Res 62:70-77
24. Kaiser E, Colescott RI, Bossinger CD, Cook P (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 34:595-598
25. Kowalczyk W, Prahl A, Derdowska I, Dawidowska O, Slaninová J, Lammek B (2004) Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin. J Med Chem 47:6020-6024
26. Kowalczyk W, Prahl A, Dawidowska O, Derdowska I, Sobolewski D, Hartrodt B, Neubert K, Slaninová J, Lammek B (2005) The influence of 1-aminocyclopentane-1-carboxylic acid at position 2 or 3 of AVP and its analogues on their pharmacological properties. J Pept Sci 11:584-588
27. Kowalczyk W, Prahl A, Derdowska I, Sobolewski D, Olejnik J, Zabrocki J, Borovickova L, Slaninova J, Lammek B (2006) Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule. J Med Chem 49:2016-2021
28. Kowalczyk W, Sobolewski D, Prahl A, Derdowska I, Borovicková L, Slaninová J, Lammek B (2007) The Effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: a highly potent V2 agonist. J Med Chem 50:2926-2929
29. Kunishima M, Kawachi C, Monta J, Terao K, Iwasaki F, Tani S (1999) 4-(4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methylmorpholinium chloride: an efficient condensing agent leading to the formation of amides and esters. Tetrahedron Lett 12: 13159-13170
30. Kwiatkowska A, Sobolewski D, Prahl A, Borovicková L, Slaninová J, Lammek B (2009) Arginine vasopressin and its analogues-the influence of position 2 modification with 3, 3-diphenylalanine enantiomers. Highly potent V2 agonists. Eur J Med Chem 44: 2862-2867
31. Kwiatkowska A, Sleszynska M, Derdowska I, Prahl A, Sobolewski D, Borovicková L, Slaninová J, Lammek B (2010) Novel analogues of arginine vasopressin containing alpha-2-indanylglycine enantiomers in position 2. J Pept Sci 16:15-20
32. Labudda O, Wierzba T, Sobolewski D, Sleszyńska M, Gawiński ?, Plackova M, Slaninová J, Prahl A (2007) New bradykinin analogues acylated on the N-terminus: effect on rat uterus and blood pressure. Acta Biochim Pol 54:193-198
33. Lammek B, Wang YX, Gavras J, Gavras H (1990) A new highly potent antagonist of bradykinin. Peptides 11:1041-1043
34. Lammek B, Wang YX, Gavras J, Gavras H (1991) A novel bradykinin antagonist with improved properties. J Pharm Pharmacol 43:887-888
35. Landgraf R, Neumann ID (2004) Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 25:150-176
36. Lebl M (1987) Analogues with inhibitory properties. In: Lebl M, Jost K, Brtnik F (eds) Handbook of neurohypophyseal hormone analogs, vol II. CRC Press, Boca Raton, pp 17-74
37. Lee HJ, Macbeth AH, Pagani JH, Young WS (2009) Oxytocin: the great facilitator of life. Prog Neurobiol 88:127-151
38. Manning M, Sawyer WH (1993) Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Receptor Res 13:195-214
39. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY (1995) Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int J Peptide Protein Res 46:244-252
40. Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C (2005) Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci 11:593-608
41. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170:473-512
42. Manning M, Stoev S, Bankowski K (2010) Peptides versus nonpeptides as therapeutics: An exciting challenge for big pharma. In: Lebl M, Mendal M, Jensen KJ, Hoeg-Jensen T (eds) Proceedings of the 31st European peptide symposium, European Peptide Society, pp 366-367
43. Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M (1986) Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 111:125-131
44. Munsick RA (1960) Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinol 66:451-458
45. Prahl A, Wierzba T, Wsze?dyby? M, Juzwa W, Lammek B (1997) Design and synthesis of new bradykinin antagonists with N-terminal acylation. Polish J Chem 71:915-922
46. Rekowski P, Lammek B (1987) Synthesis of modified analogs of 1-(1-phenylmethylthiocyclohexane)-acetic acid. Pol J Chem 61:907-911
47. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M, Chini B (2005) The oxytocin receptor antagonist atosiban inhibits cell growth via a biased agonist mechanism. J Biol Chem 280:16311-16318
48. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille J-C, Tabor B, Perry KG, Varner M, Goddwin TM, Lane R, Smith J, Shangold G, Creasy GW (2000) An oxytocin receptor antagonist (Atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 182:1173-1183
49. Sabatino G, Mulinacci B, Alcaro MC, Chelli M, Rovero P, Papini AM (2003) Assessment of new 6Cl-HOBt based coupling reagents for peptide synthesis. Part 1: coupling efficiency study. Lett Pept Sci 9:119-123
50. Saito M, Tahara A, Sugimoto T (1997) l-Desamino-8-D-arginine vasopressin (DDAVP) as an agonist on Vlb vasopressin receptor. Biochem Pharmacol 53:171-1717
51. Schnolzer M, Alewood P, Jones A, Alewood D, Kent S (1992) In situ neutralization in Boc-chemistry solid phase peptide synthesis. Int J Pept Protein Res 40:180-193
52. Slaninová J (1987) Fundamental biological evaluation. In: Lebl M, Jost K, Brtnik F (eds) Handbook of neurohypophyseal hormone analogs, vol I. CRC Press, Boca Raton, pp 83-107
53. Soloff MS, Swartz TL (1974) Characterization of proposed oxytocin receptor in the uterus of the rat and sow. J Biol Chem 249:1376-1381
54. Stewart JM (1984) Solid phase peptide synthesis. Pierce Chem. Corp, Rockford, p 87
55. Trzeciak HI, Kozik W, Melhem S, Kania A, Dobrowolski D, Prahl A, Derdowska I, Lammek B (2000) New bradykinin analogs in contraction of rat uterus. Peptides 21:829-834
56. Vande Walle J, Stockner M, Raes A, Noørgaard JP (2007) Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2:232-238
57. Vatish M, Thornton S (2002) Oxytocin antagonists. Expert Opin Ther Patents 12:1403-1406
58. Vávra I, Machová A, Krejč?́ I (1974) Antidiuretic action of 1-deamino-8-d-arginine vasopressin in unanesthetized rats. Pharmacol Exp Ther 188:241-247
59. Verbalis JG (2003) Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 17:471-503
60. Wheatley M, Howl J, Morel A, Davies ARL (1993) Homology between neurohypophysial hormone receptors. Biochem J 296:519-582
61. Zimmer S et al (1992) Schneider CH and Eberle AN (eds.) Proceedings of 22nd European Peptides Symposium, Peptides Leiden 1993, p 393
62. Zing HH, Bourque CW, Bichet DG (1998) Vasopressin and Oxytocin, Plenum Press, New York
63. Zingg HH (1996) Vasopressin and oxytocin receptors. Baillieres Clin Endocrinol Metab 10:75-96